3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Prostatic Neoplasms
1
Lymphoma, Follicular
1
Disease
1
Brain Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
3
Prednisone
2
Positron-Emission Tomography
2
Lenalidomide
2
Injections
2
Dexamethasone
2
Cyclophosphamide
2
technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid)
1
obinutuzumab
1
lortalamine
1
fluciclovine F-18
1
Vindesine
1
Vincristine
1
Transplantation, Autologous
1
Thalidomide
1
Rituximab
1
Mitomycin
1
Melphalan
1
Doxorubicin
1
Diagnosis
1
Bleomycin
1
3-Iodobenzylguanidine
1
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Disease
×
fluciclovine F-18
×
Clear all
NCT04410133
2025-08-28
REVELATE
Blue Earth Diagnostics
Phase 3
Completed
151 enrolled
29 charts